Sex-specific cytochrome P450 as a cause of sex-and species-related differences in drug toxicity

doi:10.1016/0378-4274(92)90245-F

Toxicology Letters

Volumes 64–65, December 1992, Pages 661-667

https://doi.org/10.1016/0378-4274(92)90245-F Get rights and content

Abstract

Male rats are the most frequently used experimental animals in drug toxicity tests. However, there are clear sex-related differences in toxicity of various drugs and chemicals in rats. These differences, in most cases, are closely connected with the sex-related differences in hepatic drug metabolisms. Recent studies indicate the existence of sex-specific cytochrome P450, such as P450-male (2C11) and P450-female (2C12) and P450_6β (3A2) in rat livers, and also show that their expression levels are markedly different between male and female rats. The expressions of sex-specific P450s are regulated by growth hormone, thyroid hormone, sex hormones and other chemicals. On the other hand, there are no or few cytochrome P450s that show the sex-related differences in species other than rats and mice. Although there are orthologous cytochrome P450s in viewpoints of amino acid sequence and substrate specificity in experimental animal species and humans, their expressions are not regulated by hormonal factors in most of the species. These differences may cause clear species differences, if male animals are used, in the toxicity caused by various drugs and chemicals. Thus we can predict the sex-related difference in drug toxicity on the basis of difference in the expression levels of sex-specific cytochrome P450s.

References (12)

S. Imaoka et al.
Changes in the amount of cytochrome P450s in rat hepatic microsomes with starvation
Arch. Biochem. Biophys.
(1990)
Y. Yamazoe et al.
Cytochrome P450 in livers of diabetic rats: Regulation by growth hormone and insulin
Arch. Biochem. Biophys.
(1989)
M. Shimada et al.
Suppression in the expression of a male-specific cytochrome P450, P450-male: Difference in the effect of chemical inducers on P450-male mRNA and protein in rat livers
Arch. Biochem. Biophys.
(1989)
R. Kato
Sex-related differences in drug metabolism
Drug Metab. Rev.
(1974)
R. Kato et al.
Cytochrome P-450 as a determinant of sex difference of drug metabolism in the rat
Xenobiotica
(1982)
D.W. Nebert et al.
The P450 superfamily: Update on new sequences, gene mapping, and recommended nomenclature
DNA Cell. Biol.
(1991)

There are more references available in the full text version of this article.

Cited by (161)

Oxylipin transport by lipoprotein particles and its functional implications for cardiometabolic and neurological disorders
2024, Progress in Lipid Research
Lipoprotein metabolism is critical to inflammation. While the periphery and central nervous system (CNS) have separate yet connected lipoprotein systems, impaired lipoprotein metabolism is implicated in both cardiometabolic and neurological disorders. Despite the substantial investigation into the composition, structure and function of lipoproteins, the lipoprotein oxylipin profiles, their influence on lipoprotein functions, and their potential biological implications are unclear. Lipoproteins carry most of the circulating oxylipins. Importantly, lipoprotein-mediated oxylipin transport allows for endocrine signaling by these lipid mediators, long considered to have only autocrine and paracrine functions. Alterations in plasma lipoprotein oxylipin composition can directly impact inflammatory responses of lipoprotein metabolizing cells. Similar investigations of CNS lipoprotein oxylipins are non-existent to date. However, as APOE4 is associated with Alzheimer's disease-related microglia dysfunction and oxylipin dysregulation, ApoE4-dependent lipoprotein oxylipin modulation in neurological pathologies is suggested. Such investigations are crucial to bridge knowledge gaps linking oxylipin- and lipoprotein-related disorders in both periphery and CNS. Here, after providing a summary of existent literatures on lipoprotein oxylipin analysis methods, we emphasize the importance of lipoproteins in oxylipin transport and argue that understanding the compartmentalization and distribution of lipoprotein oxylipins may fundamentally alter our consideration of the roles of lipoprotein in cardiometabolic and neurological disorders.
Nanochannel delivery system for CBD: Sustained low level plasma levels without liver toxicity
2023, Journal of Drug Delivery Science and Technology
Cannabidiol (CBD) is a plant-derived cannabinoid found in marijuana and hemp that has been intensely investigated for its putative anti-inflammatory, anxiolytic and/or analgesic effects. Since all these conditions require long-term treatment, sustained release formulations are being investigated. The nanochannel delivery system (nStrada™), an implant device containing 1 mL of CBD formulation in either sesame oil (SES) or medium-chain triglyceride (MCT) vehicles was used in a 35-day sustained-release pharmacokinetic (PK) experiment in female rats. Rats were surgically implanted with either a polyetheretherketone (PEEK) or titanium (Ti) device on day 0 (D0) and blood was obtained several times a week over 35 days. Following the maximum concentration (Cmax) at D1 of 74.3 ± 26.9 ng/mL and 26.3 ± 16.5 ng/mL in MCT and SES, respectively, the subcutaneous release of CBD from the nStrada™ implants exhibited sustained in vivo release kinetics by D14 until termination of the study on D35. The average steady-state levels were 0.8 ng/mL for CBD delivered in MCT and 0.4 ng/mL for CBD delivered in SES. At necropsy on D35, serum alanine aminotransferase (ALT) was determined, and liver histopathology was evaluated, and neither revealed liver toxicity. Skin histopathology surrounding the implanted devices revealed changes consistent with fibrosis as expected. In vitro release data confirmed consistent delivery of CBD into media containing phosphate buffered saline (PBS) with 5% Labrasol. Overall, these results provide a pre-clinical evaluation of CBD PK following implantation of a constant release device over 35 days and confirm at these CBD plasma levels, there is no concern for liver toxicity.
Diverse positional <sup>14</sup>C labeling-assisted metabolic analysis of pesticides in rats: The case of vanisulfane, a novel vanillin-derived pesticide
2022, Science of the Total Environment
Information on pesticide metabolites is crucial for accurate environmental risk assessment. However, identifying the various metabolites of a novel pesticide is challenging since the potential metabolic pathways are unknown. In this study, we coupled diverse positional ¹⁴C labeling with high-resolution mass spectrometry to quantitatively and qualitatively study pesticide metabolism in rats. With the unique M/(M + 2) ratios derived from ¹⁴C, precursor compounds of metabolites could be better distinguished from impurity ions. Additionally, the use of diverse ¹⁴C labeling positions is a powerful tool to elucidate the complete metabolic fate of novel contaminants. Vanisulfane is a novel vanillin-derived antiviral agent with encouraging prospects for the efficient control of cucumber mosaic virus in China, but its metabolic pathways in mammals are still poorly understood. Thus, the metabolism of vanisulfane was studied in rats of both sexes by this strategy. The results showed that phase I and phase II metabolism occurred in both sexes. The former included mainly oxidation reactions, and the latter involved binding reactions that formed glucuronide, sulfate and amino acid conjugates. Sex-related differences were observed in the experiment, with earlier appearance of downstream metabolites and a preference for sulfate conjugate formation in males compared to females. This research facilitates the risk evaluation of vanisulfane, and offers an effective framework for screening unknown pesticide metabolic pathways, which could be applied to establish the metabolic profiles of other novel contaminants with limited information.
CYP 450 enzymes influence (R,S)-ketamine brain delivery and its antidepressant activity
2022, Neuropharmacology
Citation Excerpt :
As a result, men display more rapid clearance of CYP1A2 substrates (e.g., caffeine, olanzapine and clozapine), CYP2E1 substrates (e.g., chlorzoxazone) and CYP2D6 substrate propranolol, metoprolol, dextromethorphan, desipramine, and mirtazapine) (Franconi et al., 2007; Schwartz, 2007; Waxman and Holloway, 2009). In rodents, sex-based differences of CYP expression is common in laboratory animals, including mice and rats, were regulated by differences in growth hormone, thyroid hormone, sex hormones and other chemicals between female and male animals (Kato and Yamazoe, 1992; Waxman and Holloway, 2009; Zanger and Schwab, 2013). More than 1,000 genes whose expression is sex-dependent have been identified in mice and rats (Waxman and Holloway, 2009).
Esketamine, the S-stereoisomer of (R,S)-ketamine was recently approved by drug agencies (FDA, EMA), as an antidepressant drug with a new mechanism of action. (R,S)-ketamine is a N-methyl-d-aspartate receptor (NMDA-R) antagonist putatively acting on GABAergic inhibitory synapses to increase excitatory synaptic glutamatergic neurotransmission. Unlike monoamine-based antidepressants, (R,S)-ketamine exhibits rapid and persistent antidepressant activity at subanesthetic doses in preclinical rodent models and in treatment-resistant depressed patients. Its major brain metabolite, (2R,6R)-hydroxynorketamine (HNK) is formed following (R,S)-ketamine metabolism by various cytochrome P450 enzymes (CYP) mainly activated in the liver depending on routes of administration [e.g., intravenous (largely used for a better bioavailability), intranasal spray, intracerebral, subcutaneous, intramuscular or oral]. Experimental or clinical studies suggest that (2R,6R)-HNK could be an antidepressant drug candidate. However, questions still remain regarding its molecular and cellular targets in the brain and its role in (R,S)-ketamine's fast-acting antidepressant effects. The purpose of the present review is: 1) to review (R,S)-ketamine pharmacokinetic properties in humans and rodents and its metabolism by CYP enzymes to form norketamine and HNK metabolites; 2) to provide a summary of preclinical strategies challenging the role of these metabolites by modifying (R,S)-ketamine metabolism, e.g., by administering a pre-treatment CYP inducers or inhibitors; 3) to analyze the influence of sex and age on CYP expression and (R,S)-ketamine metabolism. Importantly, this review describes (R,S)-ketamine pharmacodynamics and pharmacokinetics to alert clinicians about possible drug-drug interactions during a concomitant administration of (R,S)-ketamine and CYP inducers/inhibitors that could enhance or blunt, respectively, (R,S)-ketamine's therapeutic antidepressant efficacy in patients.
In utero and lactational PCB exposure drives anatomic changes in the juvenile mouse bladder
2021, Current Research in Toxicology
Bladder dysfunction, including incontinence, difficulty emptying the bladder, or urgency to urinate is a pervasive health and quality of life concern. However, risk factors for developing these symptoms are not completely understood, and the influence of exposure to environmental chemicals, especially during development, on the formation and function of the bladder is understudied. Environmental contaminants such as polychlorinated biphenyls (PCBs) are known to pose a risk to the developing brain; however, their influence on the development of peripheral target organs, such as bladder, are unknown. To address this data gap, C57Bl/6J mouse dams were exposed to an environmentally-relevant PCB mixture at 0, 0.1, 1 or 6 mg/kg daily beginning two weeks prior to mating and continuing through gestation and lactation. Bladders were collected from offspring at postnatal days (P) 28–31. PCB concentrations were detected in bladders in a dose-dependent manner. PCB effects on the bladder were sex- and dose-dependent. Overall, PCB effects were observed in male, but not female, bladders. PCBs increased bladder volume and suburothelial βIII-tubulin-positive nerve density compared to vehicle control. A subset of these nerves were sensory peptidergic axons indicated by increased calcitonin gene-related protein (CGRP) positive nerve fibers in mice exposed to the highest PCB dose compared to the lowest PCB dose. PCB-induced increased nerve density was also positively correlated with the number of mast cells in the bladder, suggesting inflammation may be involved. There were no detectable changes in epithelial composition or apoptosis as indicated by expression of cleaved caspase 3, suggesting PCBs do not cause overt toxicity. Bladder volume changes were not accompanied by changes in bladder mass or epithelial thickness, indicating that obstruction was not likely involved. Together, these results are the first to suggest that following developmental exposure, PCBs can distribute to the bladder and alter neuroanatomic development and bladder volume in male mice.
Metabolic mechanism and anti-inflammation effects of sinomenine and its major metabolites N-demethylsinomenine and sinomenine-N-oxide
2020, Life Sciences
Sinomenine (SIN) is clinically used as an anti-rheumatic drug. However, the metabolic and pharmacological mechanisms of SIN combined with its metabolites are unclear. This study aims to explore the cyclic metabolic mechanism of SIN, the anti-inflammation effects of SIN and its major metabolites (N-demethylsinomenine (DS) and sinomenine-N-oxide (SNO)), and the oxidation property of SNO.
SIN was administrated to rats via gavage. Qishe pills (a SIN-containing drug) were orally administrated to humans. The bio-samples were collected to identify SIN's metabolites. Enzymatic and non-enzymatic incubations were used to reveal SIN's metabolic mechanism. Impacts of SIN, SNO and DS on the inflammation-related cytokine's levels and nuclear translocation of NF-κB were evaluated in LPS-induced Raw264.7 cells. ROS induced by SNO (10 μM) was also assessed.
CYP3A4 and ROS predominantly mediated the formation of SNO, and CYP3A4 and CYP2C19 primarily mediated the formation of DS. Noteworthily, SNO underwent N-oxide reduction both enzymatically, by xanthine oxidase (XOD), and non-enzymatically, by ferrous ion and heme moiety. The levels of IL-6 and TNF-α and nuclear translocation of NF-κB were ameliorated after pretreatment of SIN in LPS-induced Raw264.7 cells, while limited attenuations were observed after pretreatment of DS (SNO) even at 200 μM. In contrast, SNO induced ROS production.
This study elucidated that SIN underwent both enzymatic and non-enzymatic cyclic metabolism and worked as the predominant anti-inflammation compound, while SNO induced ROS production, suggesting more studies of SIN combined with SNO and DS are necessary in case of DDI and potential toxicities.

View all citing articles on Scopus

View full text

Sex-specific cytochrome P450 as a cause of sex-and species-related differences in drug toxicity

Abstract

Arch. Biochem. Biophys.

Arch. Biochem. Biophys.

Arch. Biochem. Biophys.

Sex-related differences in drug metabolism

Drug Metab. Rev.

Cytochrome P-450 as a determinant of sex difference of drug metabolism in the rat

Xenobiotica

The P450 superfamily: Update on new sequences, gene mapping, and recommended nomenclature

DNA Cell. Biol.